Catalyst Biosciences Rises on European Orphan Designation

Shares of Catalyst Biosciences were up over 10 percent on Monday after it received orphan designation from the European Commission.

Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa

Catalyst Biosciences (NASDAQ:CBIO) has announced it has presented updated interim data from its Phase 2/3 trial of subcutaneous prophylactic Factor VIIa...

Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate

Catalyst Biosciences (NASAQ:CBIO) has announced preclinical proof-of-concept data of its gene therapy candidate, CB 2679d-GT Factor IX  gene therapy in...